Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nektar Therapeutics has announced that the US Patent and Trademark Office has issued a patent, which covers compositions and methods for creating and delivering tobramycin inhalation powder and other aminoglycoside antibiotics delivered via the company's proprietary dry powder inhaled technology.
Subscribe to our email newsletter
This patent extends through the year 2022. Tobramycin inhalation powder (TIP) is being co-developed by Nektar and Novartis and is currently in Phase III development for the prevention and treatment of Pseudomonas aeruginosa pneumonia.
Howard Robin, Nektar’s president and CEO, said: “Issuance of this patent further demonstrates the power of Nektar’s pulmonary technology platform, as well as our industry leadership in the emerging field of targeted anti-infective therapeutics. Nektar will continue to aggressively file patents to ensure that the company remains at the forefront of our fields.”